[1] Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression[J]. Anticancer Agents Med Chem, 2008, 8(7): 790-797. [2] Vaupel P1, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia[J]. Med Oncol, 2001, 18(4): 243-259. [3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. [4] He K, Wang X , Guan X, et al. Vinorelbine plus gemcitabine or cisplatin as first-line treatment of HER2-negative advanced breast cancer[J]. Anticancer Res, 2017, 37(10): 5647-5653. [5] 崔文秀, 郝吉庆.吉西他滨不同给药方式联合顺铂治疗晚期乳腺癌的临床疗效及安全性[J]. 现代肿瘤医学, 2018, 26(13): 2048-2050. [6] Shore GC, Viallet J. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer[J]. Hematology Am Soc Hematol Educ Program, 2005: 226-230. [7] 王红磊, 肖 奕, 武 力, 等. miR-449a对人乳腺癌细胞MCF-7增殖及迁移能力的影响[J].中国应用生理学杂志, 2017, 33(6): 508-513. [8] 李玉军, 李 力, 梁朝群, 等.低氧诱导因子-1α表达与胰腺癌增殖和凋亡的关系[J]. 青岛大学医学院学报, 2004, 40(1): 11-14. [9] Schwab LP, Peacock DL, Majumdar D, et al. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer[J]. Breast Cancer Res, 2012, 14(1): 1-25. [10]Copple BL. Hypoxia stimulates hepatocyte epithelial to mesenchymal transition by hypoxia-inducible factor andtransforming growth factor-beta-dependent mechanisms[J]. Liver Int, 2010, 30(5): 669-682. [11]Ito K, Park SH, Nayak A, et al. PTK6 inhibition suppresses metastases of triple-negative breast cancer via SNAIL-dependent E-Cadherin regulation[J]. Cancer Res, 2016, 76(15): 4406-4417. [12]Lazarova DL, Bordonaro M. Vimentin, colon cancer progression and resistance to butyrate and other HDACis[J]. J Cell Mol Med, 2016, 20(6): 989-993. [13]Klymenko T, Brandenburg M, Morrow C, et al. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxiainduced drug resistance in neuroblastoma cells[J]. Mol Cancer Ther, 2011, 10(12): 2373-2383. [14]Harrison LR, Micha D, Brandenburg M, et al. Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1[J]. J Clin Invest, 2011, 121(3): 1075-1087. [15]Gariboldi MB, Taiana E, Bonzi MC. The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil[J]. Cancer Lett, 2015, 364(2): 156-164. |